| Literature DB >> 17125948 |
Alejandro Diaz-Borjon1, Cornelia M Weyand, Jörg J Goronzy.
Abstract
The treatment armamentarium in rheumatic inflammatory diseases has drastically increased in the last years. Earlier uses of conventional disease-modifying antirheumatic drugs (DMARDs), along with the arrival of newer therapies including the so-called "biologic" agents, have provided better long-term outcomes for patients suffering from these illnesses. Biologic agents have shown efficacy for several diseases and failed in others. Due to a high prevalence of some of these diseases in the elderly population, this age group may also benefit, although treatment will have to be tailored to its special needs. In this mini review, we will discuss the use of these medications in rheumatic diseases with a significant prevalence in the elderly, their proven and potential uses, and the considerations that need to be taken into account when using them in this population.Entities:
Mesh：
Year: 2006 PMID： 17125948 PMCID： PMC2705938 DOI： 10.1016/j.exger.2006.10.010
Source DB: PubMed Journal: Exp Gerontol ISSN： 0531-5565 Impact factor: 4.032